ACVC Partners

Founded in 2020 and based in Palo Alto, California, ACVC Partners is a venture capital firm that invests early-stage funding into deep tech companies across sectors such as information technology, life science, mobility technology, industrials, and artificial intelligence.

Joon Lee

Managing Partner

HoChan Lee

Managing Partner

11 past transactions

Elegen

Series B in 2024
Founded in 2017 by Dr. Matthew Hill, Elegen is a biotechnology company specializing in microfluidic technology for the development of advanced DNA synthesizers. Its mission is to accelerate biomedical progress through innovative synthetic biology solutions.

EnCharge AI

Series A in 2023
EnCharge AI develops advanced artificial intelligence hardware and software systems for edge computing. The company provides an edge-to-cloud platform fabric that leverages the existing semiconductor supply chain and fits a variety of form factors to build scalable AI architectures with flexible software integration. Its solutions enable larger models, improved accuracy, higher resolutions, and multi-channel processing, helping businesses access advanced AI capabilities without costly, time-consuming workarounds. EnCharge AI focuses on delivering computing infrastructure that accelerates deployment of AI at the edge and in cloud contexts, aligning hardware and software to support diverse AI workloads.

Helm.ai

Series C in 2023
Helm.ai, founded in 2016 and based in Redwood City, California, specializes in developing advanced AI software solutions for Advanced Driver Assistance Systems (ADAS), autonomous driving, and robotics automation. The company focuses on creating full-stack real-time AI systems, including deep neural networks for both highway and urban driving scenarios, as well as end-to-end autonomous systems. Helm.ai's technology leverages unsupervised learning to train neural networks without requiring extensive fleet data or simulation, making it a key player in the development of safe and scalable autonomous technologies. The company collaborates with global automakers on production-bound projects.

Debut

Series B in 2023
Debut Biotechnology, Inc. is a biotechnology company based in San Diego, California, established in 2019. It specializes in biomanufacturing solutions for high-value molecules, focusing on the development of specialty enzyme solutions and continuous manufacturing processes. The company offers a range of services, including biomanufacturing cartridges, fermentation, and the immobilization of cells and enzymes. Debut Biotechnology is dedicated to creating novel immobilization techniques for enzymes, achieving high success rates and providing immobilized enzymes for continuous manufacturing systems. Its innovative approach enables the production and modification of small and large molecules, catering primarily to the pharmaceutical and specialty chemical industries. By harnessing natural enzyme technologies, Debut aims to deliver sustainable and cost-effective ingredient solutions to its clients.

Helm.ai

Series C in 2022
Helm.ai, founded in 2016 and based in Redwood City, California, specializes in developing advanced AI software solutions for Advanced Driver Assistance Systems (ADAS), autonomous driving, and robotics automation. The company focuses on creating full-stack real-time AI systems, including deep neural networks for both highway and urban driving scenarios, as well as end-to-end autonomous systems. Helm.ai's technology leverages unsupervised learning to train neural networks without requiring extensive fleet data or simulation, making it a key player in the development of safe and scalable autonomous technologies. The company collaborates with global automakers on production-bound projects.

Boston Materials

Series A in 2022
Boston Materials, Inc. is a manufacturer of advanced composite materials based in Bedford, Massachusetts, founded in 2016. The company specializes in producing 3D reinforced carbon fiber pre-pregs and offers a patented Z-axis Fiber technology that incorporates vertically aligned carbon fibers. This innovative approach enhances the thermal, electrical, and mechanical properties of materials, making them suitable for various high-growth industries, including semiconductors, aerospace, automotive, and renewable energy. Boston Materials' products are designed to improve performance, efficiency, and reliability while addressing challenges related to durability and weight reduction. The company employs a roll-to-roll manufacturing process with in-line quality control, achieving an annual production capacity of one million square meters.

Sepion Technologies

Series A in 2021
Sepion Technologies is an advanced membrane company based in Emeryville, California, founded in 2015. It specializes in the development of highly-tunable nanoscale membranes designed for various industrial applications, particularly in the energy storage sector. The company focuses on manufacturing innovative lithium-metal batteries by integrating nanoscience, polymer chemistry, and cell engineering. Its proprietary composite membrane serves as a cost-effective alternative to traditional ceramic separators used in lithium batteries, allowing for large-area production. This technology enables battery manufacturers to enhance energy density in their products, thereby improving overall performance and efficiency in energy storage solutions.

Debut

Series A in 2021
Debut Biotechnology, Inc. is a biotechnology company based in San Diego, California, established in 2019. It specializes in biomanufacturing solutions for high-value molecules, focusing on the development of specialty enzyme solutions and continuous manufacturing processes. The company offers a range of services, including biomanufacturing cartridges, fermentation, and the immobilization of cells and enzymes. Debut Biotechnology is dedicated to creating novel immobilization techniques for enzymes, achieving high success rates and providing immobilized enzymes for continuous manufacturing systems. Its innovative approach enables the production and modification of small and large molecules, catering primarily to the pharmaceutical and specialty chemical industries. By harnessing natural enzyme technologies, Debut aims to deliver sustainable and cost-effective ingredient solutions to its clients.

Boston Materials

Series A in 2021
Boston Materials, Inc. is a manufacturer of advanced composite materials based in Bedford, Massachusetts, founded in 2016. The company specializes in producing 3D reinforced carbon fiber pre-pregs and offers a patented Z-axis Fiber technology that incorporates vertically aligned carbon fibers. This innovative approach enhances the thermal, electrical, and mechanical properties of materials, making them suitable for various high-growth industries, including semiconductors, aerospace, automotive, and renewable energy. Boston Materials' products are designed to improve performance, efficiency, and reliability while addressing challenges related to durability and weight reduction. The company employs a roll-to-roll manufacturing process with in-line quality control, achieving an annual production capacity of one million square meters.

DarwinAI

Seed Round in 2020
DarwinAI Corp. is a Canadian company that specializes in artificial intelligence technology, particularly in the development of deep neural networks for enterprise applications. Founded in 2017 and based in Waterloo, the company offers GenSynth, a software platform designed for developers and data scientists to streamline the deep learning development process. GenSynth employs generative synthesis technology, allowing for the automatic creation of optimized, explainable AI models that meet specific performance criteria while ensuring transparency throughout the development stages. Additionally, DarwinAI has developed an AI-powered visual quality inspection system aimed at enhancing the PCBA manufacturing lifecycle. This system leverages specialized optics and advanced algorithms to detect defects in products, improving quality and consistency while reducing costs for manufacturers.

Medable

Series C in 2020
Medable operates a global decentralized trial platform that connects patients, sites, and clinical trial teams. It streamlines trial design, recruitment, retention, and data quality, replacing siloed systems with integrated digital tools, data, and interfaces to accelerate trial execution. The platform ensures patient access, improves experience, and enhances outcomes while adhering to healthcare sector's strict compliance, interoperability, and privacy concerns.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.